Charl Zyl - UCB SA President
| UCBJF Stock | USD 174.00 0.00 0.00% |
President
Mr. Charl van Zyl has served as Executive Vice President, Chief Operating Officer, Member of the Executive Committee of UCB S.A. since March 1, 2017. As of 2014, he served as Executive Vice President, Global Commercial Head and Head of LatamCanada at BSN Medical. From 2009 to 2013 he worked for Bauch Lomb as Executive Vice President, President of EMEA and from 2007 to 2009 he was Chief Executive Officer of Jado Technologies . From 2004 to 2007 he served at Novartis as Head Marketing and Sales EMEA and Head of Global Marketing. Moreover, he was Marketing Manager Diabetes Care and Neurosciences LatamCanada and South Africa Marketing Manager Japan at Eli Lilly from 1995 to 2004. In 1991 he graduated from University of Cape Town, South Africa in Medical Biochemistry and in 1999 in Business Administration executive program from the same university. since 2017.
| Age | 56 |
| Tenure | 7 years |
| Phone | 32 2 559 99 99 |
| Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | PRESIDENT Age | ||
| Robb Knie | Hoth Therapeutics | 55 | |
| Massimo MBA | Jaguar Animal Health | 66 | |
| Kanya MD | Senti Biosciences | 50 | |
| Weidong Dai | Fresh2 Group | 63 | |
| Raquel Izumi | Vincerx Pharma | 54 | |
| Juan Jaen | Arcus Biosciences | 66 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 |
UCB SA Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sandrine CFA, Ex CFO | ||
| Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
| William Silbey, Exec Counsel | ||
| Pr LowFriedrich, Chief VP | ||
| Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
| Kirsten LundJurgensen, Ex Solutions | ||
| Caroline Vancoillie, Chief Functions | ||
| JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
| JeanChristophe Tellier, Chairman of the Executive Committee, CEO |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 17.07 B | |||
| Shares Outstanding | 189.96 M | |||
| Shares Owned By Insiders | 38.03 % | |||
| Shares Owned By Institutions | 40.78 % | |||
| Price To Earning | 17.62 X | |||
| Price To Book | 1.52 X |
Currently Active Assets on Macroaxis
Other Information on Investing in UCB Pink Sheet
UCB SA financial ratios help investors to determine whether UCB Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in UCB with respect to the benefits of owning UCB SA security.